Sugi Predict

Sugi Predict / Compounds / SCHEMBL6174196

SCHEMBL6174196

SCHEMBL6174196

CC(C)(C)OC(=O)n1cnc2cc(C(=O)O)ccc21

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ HCAR3 P49019 3/20 0.53
▸ HPGD P15428 3/20 0.50
▸ FGFR1 P11362 3/20 0.50
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ TSHR P16473 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ THRB P10828 1/20 0.45
▸ RIPK1 Q13546 1/20 0.43
▸ RIPK3 Q9Y572 1/20 0.43
▸ RXRA P19793 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34467402 0.89 FGFR1 (0.51) HCAR3HPGDFGFR1ALDH1A1RIPK1
SCHEMBL2143624 0.89 FGFR1 (0.50) HCAR3HPGDFGFR1ALDH1A1LMNA
SCHEMBL30962501 0.89 FGFR1 (0.50) HCAR3HPGDFGFR1ALDH1A1LMNA
SCHEMBL832377 0.83 GABRG2 (0.44) HPGDFGFR1GAARIPK1RIPK3
SCHEMBL1455275 0.83 HTR6 (0.47) HPGDFGFR1RIPK1RIPK3
SCHEMBL1418125 0.83 RIPK1 (0.48) HPGDALDH1A1LMNARIPK1RIPK3
SCHEMBL559567 0.82 SIK1 (0.44) LMNARIPK1RIPK3
SCHEMBL4819554 0.82 GABRG2 (0.49) HPGDALDH1A1RIPK1RIPK3
SCHEMBL30847454 0.82 SIK1 (0.44) LMNARIPK1RIPK3
SCHEMBL482648 0.82 NR1H2 (0.43) FGFR1ALDH1A1HSD17B10RIPK1RIPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634162-A1 BENZIMIDAZOLE DERIVATIVES Syngenta Crop Protection AG (CH) 2025-10-22 — — EP disclosed
WO-2024126407-A1 BENZIMIDAZOLE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2024-06-20 — — WO disclosed
EP-3350177-B1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-07-07 — — EP disclosed
US-10392375-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2019-08-27 — — US disclosed
US-10059701-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2018-08-28 — — US disclosed
US-20180237426-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2018-08-23 — — US disclosed
US-9740098-B2 Chemically amplified negative resist composition using novel onium salt and resist pattern forming process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-08-22 — — US disclosed
US-9720323-B2 Chemically amplified positive resist composition and pattern forming process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-08-01 — — US disclosed
US-20170081317-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-03-23 — — US disclosed
EP-3081987-A2 CHEMICALLY AMPLIFIED NEGATIVE RESIST COMPOSITION USING NOVEL ONIUM SALT AND RESIST PATTERN FORMING PROCESS Shin-Etsu Chemical Co., Ltd. (JP) 2016-10-19 — — EP disclosed
EP-3062150-A2 CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS Shin-Etsu Chemical Co., Ltd. (JP) 2016-08-31 — — EP disclosed
US-20160246175-A1 CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-08-25 — — US disclosed
EP-1311501-B1 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2005-11-02 — — EP disclosed
US-6924296-B2 Antithrombotic agents ELI LILLY AND COMPANY (US) 2005-08-02 — — US disclosed
WO-2005023986-A2 MICRORNA AS LIGANDS AND TARGET MOLECULES ISIS PHARMACEUTICALS, INC. (US) 2005-03-17 — — WO disclosed
US-20040010017-A1 Antithrombotic agents ELI LILLY AND COMPANY 2004-01-15 — — US disclosed
US-20040006104-A1 Neutrophil inhibitors to reduce inflammatory response THE PROCTER & GAMBLE COMPANY 2004-01-08 — — US disclosed
EP-1311501-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2003-05-21 — — EP disclosed
WO-2002016327-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS NEUTROPHIL INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-02-28 — — WO disclosed
WO-2002014308-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2002-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180237426-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 HCAR3 1129/4885HPGD 4202/4885FGFR1 1134/4885
US-20170081317-A1 HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 HCAR3 1129/4885HPGD 4202/4885FGFR1 1134/4885
US-20040006104-A1 Neutrophil inhibitors to reduce inflammatory response MPO, SERPINB1, NCF1 HCAR3 379/4885HPGD 187/4885FGFR1 2126/4885
US-10392375-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof IRAK2, IRAK3, IRAK1 HCAR3 1129/4885HPGD 4202/4885FGFR1 1134/4885
US-20040010017-A1 Antithrombotic agents SERPINC1, TFPI, F11 HCAR3 1865/4885HPGD 225/4885FGFR1 2080/4885
US-10059701-B2 Heteroaryl compounds as IRAK inhibitors and uses thereof IRAK2, IRAK3, IRAK1 HCAR3 1129/4885HPGD 4202/4885FGFR1 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.